What is Haleon PLC?
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
HLN · Verdict
Solid reward · low risk
HLN scores well on volatility and cash flow with no major weaknesses flagged in the model.
Based on 88% data coverage
HLN · Verdict
Top decile vs peers
18% free-cash-flow margin
15% net margin · 9% ROE
Model-based scoring. For information only — not financial advice.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 33.53B, and a P/E ratio of 22.1x.
The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.